Showing results (21-30 of 54) with videos related to
Sort By:
Pageof 6
Clinical Pharmacokinetics|June 20, 2018
Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor AgonistSylvie Hall, Diana Isaacs, Jennifer N ClementsClinical Pharmacokinetics|July 7, 2018
Faster Insulin Aspart: A New Bolus Option for Diabetes MellitusAbigayle Davis, Jolly Kuriakose, Jennifer N ClementsJournal of Pharmacy Practice|October 6, 2017
Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With GoutEmily Huneycutt, Chase Board, Jennifer N ClementsTouchreviews in Endocrinology|November 17, 2025
A Clinical Review of Continuous Glucose Monitoring in the Hospital SettingJennifer N Clements, Kennedy Howard, Emory MossJournal of Pharmacy Practice|August 14, 2016
Drug-Induced Vitamin B<sub>12</sub> Deficiency: A Focus on Proton Pump Inhibitors and Histamine-2 AntagonistsLauren Linder, Cynthia Tamboue, Jennifer N ClementsExpert Review of Endocrinology & Metabolism|July 31, 2018
Liraglutide, GLP-1 receptor agonist, for chronic weight lossKatherine G Moore, Kayce Shealy, Jennifer N ClementsThe Mental Health Clinician|June 30, 2018
What's new in multiple sclerosis?Erika E Tillery, Jennifer N Clements, Zach HowardDiabetes, Metabolic Syndrome and Obesity : Targets and Therapy|May 24, 2019
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to dateRebecca Howell, Adrienne M Wright, Jennifer N ClementsThe Annals of Pharmacotherapy|November 10, 2011
The value of pharmacy services on a short-term medical mission trip: description of services and assessment of team satisfactionJennifer N Clements, Michelle L Rager, Emily M VescoviClinical Pharmacokinetics|October 27, 2020
Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes MellitusJennifer N Clements, Diana Isaacs, Rachel E Hartman, et al.Pageof 6